Should You Buy Plus Therapeutics Inc (PSTV) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
0.250
1 Day change
4.18%
52 Week Range
2.310
Analysis Updated At
2026/01/26
Plus Therapeutics Inc (PSTV) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently in a bearish trend, with oversold technical indicators but no clear positive trading signals. While the company has promising developments in its clinical programs, recent financial performance and equity dilution raise concerns. It is better to wait for stronger catalysts or improved financial and technical conditions before investing.
Technical Analysis
The stock is in a bearish trend with negative MACD (-0.0234) and oversold RSI (15.035). Moving averages indicate a downward trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 0.267), but there is no indication of a reversal yet.
Options Data
Positive Catalysts
The company has extended its cash runway through 2027, and its clinical program advancements in precision radiotherapeutics for CNS cancers could provide long-term growth potential. Analysts highlight a 'catalyst-rich' 2026.
Neutral/Negative Catalysts
Recent equity dilution has led to lowered price targets by analysts. The company's financials show a YoY revenue decline (-4.05%) and a significant EPS drop (-89.19%). The stock is currently in a bearish technical setup.
Financial Performance
In 2025/Q3, revenue dropped by -4.05% YoY to $1,397,000. Net income improved to -$4,423,000 (up 53.90% YoY), but EPS dropped significantly to -0.04 (-89.19% YoY). Gross margin remained stable at 100%.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts maintain a Buy rating but have significantly lowered price targets due to equity dilution. Maxim reduced the target to $1.50 from $3, and H.C. Wainwright reduced it to $1 from $2.
Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 8 USD with a low forecast of 2 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 8 USD with a low forecast of 2 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.239
Low
2
Averages
8
High
19
Current: 0.239
Low
2
Averages
8
High
19
Maxim
Maxim
Buy
downgrade
$3
AI Analysis
2026-01-23
Reason
Maxim
Maxim
Price Target
$3
AI Analysis
2026-01-23
downgrade
Buy
Reason
Maxim lowered the firm's price target on Plus Therapeutics to $1.50 from $3 and keeps a Buy rating on the shares. The company's ReSPECT-LM Phase 2 dose-optimization study continues to enroll, with data expected in Q3, and following encouraging feedback from its recent Type B meeting with the FDA, Plus plans to advance into a potentially pivotal leptomeningeal metastases study after completion of the current dose-optimization phase, though the firm is adjusting its model to reflect the dilution from the company's recent financing, the analyst tells investors in a research note.
H.C. Wainwright
Sean Lee
Buy
downgrade
$2 -> $1
2026-01-23
Reason
H.C. Wainwright
Sean Lee
Price Target
$2 -> $1
2026-01-23
downgrade
Buy
Reason
H.C. Wainwright analyst Sean Lee lowered the firm's price target on Plus Therapeutics to $1 from $2 and keeps a Buy rating on the shares. The firm cites diluting from the company's recent equity offering for the target cut. It sees a "catalyst-rich" 2026 for Plus Therapeutics.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PSTV
